August 28, 2018

SimpliciTB Clinical Trial Launched with First Patients in Tbilisi, Georgia

New pivotal trial examines potential of BPaMZ regimen to shorten treatment for tuberculosis and multidrug-resistant tuberculosis
August 17, 2018

TB Alliance Statement on WHO Rapid Communication Regarding MDR-TB Treatment

Forthcoming Recommendations Point to Treatment Changes for Drug-Resistant TB
July 13, 2018

TB Alliance Names Angela Vanderploeg as Chief Financial Officer

Vanderploeg Brings Comprehensive Financial Management Experience to Help Guide Pursuit of Life-Saving New Tuberculosis Therapies
July 6, 2018

In Memory of Professor Denis Mitchison

Statement from TB Alliance
June 5, 2018

Statement on Civil Society Hearing on the UN High Level Meeting on Tuberculosis

PDPs urge commitment to tripling the overall annual investments in TB R&D
June 4, 2018

TB Alliance Names Sandeep Juneja as Senior Vice President for Market Access

Juneja Brings Industry Expertise to Initiatives that Accelerate Access to New TB Drug Regimens
April 26, 2018

Global MPs Urge Heads of State to Act on Tuberculosis

Parliamentarians from around the world are calling for heads of state to bring the global epidemic of tuberculosis (TB) to an end
March 29, 2018

After World TB Day, High Expectations for Action

A message from Mel Spigelman, TB Alliance President and CEO
March 6, 2018

Nancy Miller-Rich Joins TB Alliance Board of Directors

Miller-Rich has 35 years of experience in the pharmaceutical industry, including global business development at Merck Pharmaceuticals
February 7, 2018

ZeNix Clinical Trial Announced

New trial evaluates whether the efficacy of the BPaL drug regimen can be maintained with reduced toxicity

Pages